We observed a rebound of AKT and mTOR phosphorylation after a 24-hour incubation with these PI3K inhibitors, which was more apparent in idelalisib-treated MCC-3 and MCC-9 (upper and middle panels in Fig. 4B). The gene discussed is PIK3CD; the disease is Merkel cell skin cancer.